Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

NOURIANZ (istradefylline) for the Treatment of Parkinson’s Disease

Drug Name

NOURIANZ (istradefylline)

Developer

Kyowa Kirin

Therapy Class

Adenosine A2A receptor antagonist

Product Description

Combination therapy with levodopa and carbidopa

Current Indication

Parkinson's Disease

Market Sector

Central nervous system (CNS)

Development Status

Approved in Japan and the US
Expand
Close
Close
Close

Go Top